

# Jordan Feld

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8445079/jordan-feld-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

309  
papers

15,830  
citations

64  
h-index

119  
g-index

373  
ext. papers

18,896  
ext. citations

7.6  
avg, IF

6.75  
L-index

#	Paper	IF	Citations
309	Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 308, 2584-93	27.4	1089
308	Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. <i>New England Journal of Medicine</i> , <b>2013</b> , 368, 1867-77	59.2	885
307	Mechanism of action of interferon and ribavirin in treatment of hepatitis C. <i>Nature</i> , <b>2005</b> , 436, 967-72	50.4	795
306	Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 2599-607	59.2	758
305	Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 1594-603	59.2	690
304	Residual NADPH oxidase and survival in chronic granulomatous disease. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 2600-10	59.2	397
303	Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. <i>Gastroenterology</i> , <b>2005</b> , 128, 1437-44	13.3	390
302	Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 354-369	59.2	281
301	From non-A, non-B hepatitis to hepatitis C virus cure. <i>Journal of Hepatology</i> , <b>2015</b> , 62, S87-99	13.4	231
300	Extrahepatic morbidity and mortality of chronic hepatitis C. <i>Gastroenterology</i> , <b>2015</b> , 149, 1345-60	13.3	230
299	Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. <i>Hepatology</i> , <b>2005</b> , 42, 53-62	11.2	230
298	Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. <i>Hepatology</i> , <b>2007</b> , 46, 1548-63	11.2	218
297	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 135-184	18.8	216
296	Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. <i>Gastroenterology</i> , <b>2010</b> , 138, 325-35.e1-2	13.3	211
295	Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. <i>Hepatology</i> , <b>2015</b> , 62, 79-86	11.2	207
294	Increased caffeine consumption is associated with reduced hepatic fibrosis. <i>Hepatology</i> , <b>2010</b> , 51, 201-9	11.2	207
293	Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 29, 172-82	6.1	197

292	Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. <i>Gastroenterology</i> , <b>2017</b> , 153, 113-122	13.3	180
291	Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 485-493	13.4	160
290	Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 153-161	18.8	155
289	Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. <i>Gastroenterology</i> , <b>2016</b> , 150, 419-29	13.3	140
288	Integrated quantum dot barcode smartphone optical device for wireless multiplexed diagnosis of infected patients. <i>ACS Nano</i> , <b>2015</b> , 9, 3060-74	16.7	137
287	Recommendations for the management of hepatitis C virus infection among people who inject drugs. <i>International Journal of Drug Policy</i> , <b>2015</b> , 26, 1028-38	5.5	132
286	Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. <i>Gastroenterology</i> , <b>2019</b> , 157, 1264-1278.e4	13.3	130
285	Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. <i>Gastroenterology</i> , <b>2011</b> , 141, 1231-9, 1239.e1-2	13.3	129
284	Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2212-20	2.2	128
283	Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. <i>Gastroenterology</i> , <b>2016</b> , 150, 684-695.e5	13.3	126
282	Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 301-307	13.4	125
281	American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3199-202	2.2	124
280	Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. <i>Hepatology</i> , <b>2011</b> , 53, 32-41	11.2	123
279	The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. <i>Antiviral Research</i> , <b>2007</b> , 76, 168-77	10.8	122
278	Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2016</b> , 13, 338-51	24.2	122
277	Hepatitis C virus therapeutic development: in pursuit of "perfectovir". <i>Clinical Infectious Diseases</i> , <b>2015</b> , 60, 1829-36	11.6	105
276	Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. <i>Hepatology</i> , <b>2008</b> , 48, 550-6	11.2	104
275	Ribavirin improves early responses to peginterferon through improved interferon signaling. <i>Gastroenterology</i> , <b>2010</b> , 139, 154-62.e4	13.3	100

274	What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?. <i>Gastroenterology</i> , <b>2019</b> , 156, 446-460.e2	13.3	99
273	Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. <i>Gastroenterology</i> , <b>2007</b> , 132, 733-44	13.3	94
272	Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. <i>Gastroenterology</i> , <b>2010</b> , 138, 1123-33.e1-3	13.3	92
271	Clinical Validation of Quantum Dot Barcode Diagnostic Technology. <i>ACS Nano</i> , <b>2016</b> , 10, 4742-53	16.7	92
270	Hepatic abnormalities in patients with chronic granulomatous disease. <i>Hepatology</i> , <b>2007</b> , 45, 675-83	11.2	90
269	Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 498-510	35.1	89
268	Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. <i>Journal of Viral Hepatitis</i> , <b>2015</b> , 22, 842-9	3.4	88
267	Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. <i>Hepatology</i> , <b>2012</b> , 55, 39-48	11.2	88
266	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 539-557	13.4	88
265	Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 33-39	13.4	86
264	Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis. <i>Expert Review of Molecular Diagnostics</i> , <b>2017</b> , 17, 1109-1115	3.8	86
263	Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3167-73	2.2	84
262	Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. <i>Gastroenterology</i> , <b>2019</b> , 156, 1683-1692.e1	13.3	79
261	Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 867-76	6.1	78
260	Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. <i>Journal of Hepatology</i> , <b>2017</b> ,	13.4	78
259	Tratamiento del VHB en pacientes que van a recibir terapia inmunosupresora. <i>Clinical Liver Disease</i> , <b>2013</b> , 2, S28-S32	2.2	78
258	Segue desempeñando alg� papel la cin�tica viral durante el tratamiento de la infecci� por el VHC?. <i>Clinical Liver Disease</i> , <b>2013</b> , 2, S24-S27	2.2	78
257	Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. <i>Gastroenterology</i> , <b>2019</b> , 157, 1253-1263.e2	13.3	77

256	Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. <i>Journal of Infectious Diseases</i> , <b>2010</b> , 202, 845-52	7	75
255	Immigration and viral hepatitis. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 515-22	13.4	73
254	Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 63, 1479-1481	11.6	72
253	Hepatitis C -- identifying patients with progressive liver injury. <i>Hepatology</i> , <b>2006</b> , 43, S194-206	11.2	71
252	Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1298-1308	0.7	70
251	Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 283-93	6.1	70
250	Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 183-92	6.9	68
249	Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 312, 1927-8	27.4	68
248	Hepatic involvement and portal hypertension predict mortality in chronic granulomatous disease. <i>Gastroenterology</i> , <b>2008</b> , 134, 1917-26	13.3	68
247	Epidemiology of autoimmune liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2003</b> , 18, 1118-28	4	68
246	Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B. <i>Hepatology</i> , <b>2007</b> , 46, 1057-70	11.2	67
245	The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. <i>Cmaj</i> , <b>2018</b> , 190, E677-E687	3.5	62
244	Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. <i>Liver International</i> , <b>2017</b> , 37, 5-18	7.9	62
243	Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 421-430.e6	6.9	62
242	An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2012</b> , 26, 359-75		62
241	Endpoints of therapy in chronic hepatitis B. <i>Hepatology</i> , <b>2009</b> , 49, S96-S102	11.2	61
240	Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study). <i>Gut</i> , <b>2019</b> , 68, 2206-2213	19.2	59
239	An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2015</b> , 29, 19-34	2.8	59

238	Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. <i>CMAJ Open</i> , <b>2016</b> , 4, E605-E614	2.5	59
237	Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: A validation study. <i>PLoS ONE</i> , <b>2018</b> , 13, e0201120	3.7	53
236	Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. <i>Gastroenterology</i> , <b>2012</b> , 142, 1122-1131.e1	13.3	53
235	Health care costs associated with hepatocellular carcinoma: a population-based study. <i>Hepatology</i> , <b>2013</b> , 58, 1375-84	11.2	52
234	Acute spontaneous tumor lysis syndrome in adenocarcinoma of the lung: a case report. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2000</b> , 23, 491-3	2.7	52
233	A research agenda for curing chronic hepatitis B virus infection. <i>Hepatology</i> , <b>2018</b> , 67, 1127-1131	11.2	51
232	Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. <i>Hepatology</i> , <b>2013</b> , 57, 2124-34	11.2	51
231	Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression. <i>Clinical Gastroenterology and Hepatology</i> , <b>2009</b> , 7, 1130-7	6.9	51
230	Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B. <i>Hepatology</i> , <b>2020</b> , 71, 539-548	11.2	51
229	Cost-effectiveness of screening for hepatitis C in Canada. <i>Cmaj</i> , <b>2015</b> , 187, E110-E121	3.5	50
228	New therapeutic agents for chronic hepatitis B. <i>Lancet Infectious Diseases, The</i> , <b>2016</b> , 16, e10-21	25.5	49
227	Inactivating hepatitis C virus in donor lungs using light therapies during normothermic ex vivo lung perfusion. <i>Nature Communications</i> , <b>2019</b> , 10, 481	17.4	48
226	Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. <i>Gut</i> , <b>2014</b> , 63, 161-9	19.2	48
225	Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 1821-1830.e6	6.9	46
224	Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial. <i>Lancet Respiratory Medicine, the</i> , <b>2020</b> , 8, 192-201	35.1	45
223	Inducing Hepatitis C Virus Resistance After Pig Liver Transplantation-A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion. <i>American Journal of Transplantation</i> , <b>2017</b> , 17, 970-978	8.7	44
222	Abnormal intestinal permeability in primary biliary cirrhosis. <i>Digestive Diseases and Sciences</i> , <b>2006</b> , 51, 1607-13	4	44
221	Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1840-1849.e16	6.9	43

220	Clinical utility of HCV core antigen detection and quantification in the diagnosis and management of patients with chronic hepatitis C receiving an all-oral, interferon-free regimen. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 211-217	1.6	42
219	Interferon-free strategies with a nucleoside/nucleotide analogue. <i>Seminars in Liver Disease</i> , <b>2014</b> , 34, 37-46	7.3	40
218	Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. <i>International Journal of Drug Policy</i> , <b>2017</b> , 47, 51-60	5.5	40
217	Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 37, 887-94	6.1	40
216	S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders. <i>Gastroenterology</i> , <b>2011</b> , 140, 830-9	13.3	40
215	Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 649-657	18.8	38
214	Approaches for simplified HCV diagnostic algorithms. <i>Journal of the International AIDS Society</i> , <b>2018</b> , 21 Suppl 2, e25058	5.4	38
213	Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2016</b> , 1, 25-35	18.8	38
212	Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 494-500	18.8	37
211	Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 63, 776-783	11.6	37
210	Noninvasive markers of fibrosis: key concepts for improving accuracy in daily clinical practice. <i>Annals of Hepatology</i> , <b>2012</b> , 11, 426-439	3.1	35
209	New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. <i>Hepatology</i> , <b>2003</b> , 38, 545-53	11.2	35
208	Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. <i>International Journal of Drug Policy</i> , <b>2018</b> , 62, 14-23	5.5	35
207	Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis. <i>Liver International</i> , <b>2018</b> , 38, 443-450	7.9	34
206	The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection. <i>Gut</i> , <b>2016</b> , 65, 1347-58	19.2	33
205	Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 1168-76	4	33
204	Liver injury is associated with mortality in sickle cell disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 912-21	6.1	33
203	Influence of socioeconomic status on survival of hepatocellular carcinoma in the Ontario population; a population-based study, 1990-2009. <i>PLoS ONE</i> , <b>2012</b> , 7, e40917	3.7	33

202	The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals. <i>Journal of Virus Eradication</i> , <b>2019</b> , 5, 60-66	2.8	33
201	Role of Serologic and Molecular Diagnostic Assays in Identification and Management of Hepatitis C Virus Infection. <i>Journal of Clinical Microbiology</i> , <b>2016</b> , 54, 265-73	9.7	32
200	Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3698-3715	2.2	32
199	HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 856-864	18.8	32
198	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 1066-1074	0.7	31
197	A Canadian screening program for hepatitis C: is now the time?. <i>Cmaj</i> , <b>2013</b> , 185, 1325-8	3.5	31
196	Is there sufficient evidence to recommend antiviral therapy in hepatitis C?. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 191-6	13.4	30
195	Hepatitis B e antigen-positive chronic hepatitis B: natural history and treatment. <i>Seminars in Liver Disease</i> , <b>2006</b> , 26, 116-29	7.3	30
194	Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. <i>Gut</i> , <b>2015</b> , 64, 322-31	19.2	28
193	Second generation direct-acting antivirals - Do we expect major improvements?. <i>Journal of Hepatology</i> , <b>2016</b> , 65, S130-S142	13.4	28
192	Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, e115-e124	11.6	28
191	Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, ofy001	1	27
190	Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review. <i>Hepatology Communications</i> , <b>2017</b> , 1, 379-390	6	26
189	The beginning of the end: what is the future of interferon therapy for chronic hepatitis C?. <i>Antiviral Research</i> , <b>2014</b> , 105, 32-8	10.8	25
188	Progress towards hepatitis C virus elimination in high-income countries: An updated analysis. <i>Liver International</i> , <b>2021</b> , 41, 456-463	7.9	25
187	HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients. <i>Journal of Virological Methods</i> , <b>2017</b> , 245, 14-18	2.6	24
186	Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy. <i>Liver International</i> , <b>2015</b> , 35, 1923-33	7.9	24
185	HCV persistence: cure is still a four letter word. <i>Hepatology</i> , <b>2005</b> , 41, 23-5	11.2	24



184	Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 65, 680-683	11.6	23
183	Ribavirin improves the IFN- $\gamma$ response of natural killer cells to IFN-based therapy of hepatitis C virus infection. <i>Hepatology</i> , <b>2014</b> , 60, 1160-9	11.2	23
182	Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection. <i>Aids</i> , <b>2012</b> , 26, 1653-61	3.5	23
181	Antiviral therapy for hepatitis B virus infections: new targets and technical challenges. <i>Journal of Clinical Virology</i> , <b>2002</b> , 25, 267-83	14.5	23
180	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Hepatology</i> , <b>2019</b> , 71, 1070	11.2	23
179	Review article: clinical pharmacology of current and investigational hepatitis B virus therapies. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 231-243	6.1	23
178	Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1053-1063	13.4	23
177	Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 406-417	18.8	22
176	Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma?. <i>Seminars in Liver Disease</i> , <b>2013</b> , 33, 157-66	7.3	22
175	Lipopolysaccharide and Tumor Necrosis Factor Alpha Inhibit Interferon Signaling in Hepatocytes by Increasing Ubiquitin-Like Protease 18 (USP18) Expression. <i>Journal of Virology</i> , <b>2016</b> , 90, 5549-5560	6.6	22
174	Estimating chronic hepatitis C prognosis using transient elastography-based liver stiffness: A systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 502-513	3.4	22
173	Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening. <i>PLoS ONE</i> , <b>2015</b> , 10, e0120749	3.7	21
172	Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 65, 13-19	11.6	20
171	Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 294-302	13.4	20
170	Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 62, 1228-1234	11.6	19
169	Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 1027-35	6.1	19
168	The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21, 568-77	3.4	18
167	Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 482-91	13.4	18

166	The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 781-793	3.4	17
165	The development and validation of magnetic resonance elastography for fibrosis staging in primary sclerosing cholangitis. <i>European Radiology</i> , <b>2019</b> , 29, 1039-1047	8	17
164	Protein interferon-stimulated gene 15 conjugation delays but does not overcome coronavirus proliferation in a model of fulminant hepatitis. <i>Journal of Virology</i> , <b>2014</b> , 88, 6195-204	6.6	17
163	Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, 202-211	11.6	17
162	Flu-like symptoms and associated immunological response following therapy with botulinum toxins. <i>Neurotoxicity Research</i> , <b>2013</b> , 24, 298-306	4.3	16
161	Model-based projection of health and economic effects of screening for hepatitis C in Canada. <i>CMAJ Open</i> , <b>2017</b> , 5, E662-E672	2.5	16
160	Defining and grading HBV reactivation. <i>Clinical Liver Disease</i> , <b>2015</b> , 5, 35-38	2.2	16
159	Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2541-2551.e2	6.9	15
158	Population-based estimate of hepatitis C virus prevalence in Ontario, Canada. <i>PLoS ONE</i> , <b>2018</b> , 13, e0191184	3.74	15
157	Arresting the time-dependent HO mediated synthesis of gold nanoparticles for analytical detection and preparative chemistry. <i>Journal of Materials Chemistry B</i> , <b>2013</b> , 1, 4048-4051	7.3	15
156	Symptomatic and pathophysiologic predictors of hepatitis C virus progression in pediatric patients. <i>Pediatric Infectious Disease Journal</i> , <b>2009</b> , 28, 724-7	3.4	15
155	Race or genetic makeup for hepatitis C virus treatment decisions?. <i>Hepatology</i> , <b>2017</b> , 65, 2124-2125	11.2	14
154	Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis. <i>CMAJ Open</i> , <b>2017</b> , 5, E97-E108	1.98	14
153	The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 46-55	6.1	14
152	Acute hepatitis C: management in the rapidly evolving world of HCV. <i>Current Gastroenterology Reports</i> , <b>2014</b> , 16, 371	5	14
151	Is there a role for ribavirin in the era of hepatitis C virus direct-acting antivirals?. <i>Gastroenterology</i> , <b>2012</b> , 142, 1356-9	13.3	14
150	Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection. <i>Hepatology</i> , <b>2019</b> , 69, 2338-2348	11.2	14
149	Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. <i>International Journal of Drug Policy</i> , <b>2018</b> , 62, 94-103	5.5	14

148	Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B. <i>Diabetes Care</i> , <b>2018</b> , 41, 1251-1259	14.6	13
147	Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2012</b> , 26, 429-44	2.5	13
146	Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 431-440	13.4	13
145	Treatment of hepatitis B virus with combination therapy now and in the future. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2017</b> , 31, 347-355	2.5	12
144	Simplification of Care for Chronic Hepatitis C Virus Infection. <i>Seminars in Liver Disease</i> , <b>2020</b> , 40, 392-402	7.3	12
143	What Comes First: Treatment of Viral Hepatitis or Liver Cancer?. <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 1041-1049	4	11
142	Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 856-865	3.4	11
141	Liver stiffness increases acutely during sickle cell vaso-occlusive crisis. <i>American Journal of Hematology</i> , <b>2013</b> , 88, E250-4	7.1	11
140	Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues. <i>Current Drug Targets</i> , <b>2017</b> , 18, 851-862	3	11
139	Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update. <i>BMJ Open</i> , <b>2019</b> , 9, e027491	3	11
138	Hepatitis C Core-Antigen Testing from Dried Blood Spots. <i>Viruses</i> , <b>2019</b> , 11,	6.2	10
137	Implications of Manganese in Chronic Acquired Hepatocerebral Degeneration. <i>Annals of Hepatology</i> , <b>2019</b> , 18, 274-278	3.1	10
136	The effectiveness of ultrasound surveillance for hepatocellular carcinoma in a Canadian centre and determinants of its success. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2015</b> , 29, 267-73	2.8	10
135	I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis. <i>F1000Research</i> , <b>2015</b> , 4, 95	3.6	10
134	Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, 1392-1400	11.6	10
133	Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 151, 639-52	4.4	9
132	The emergency department as a setting-specific opportunity for population-based hepatitis C screening: An economic evaluation. <i>Liver International</i> , <b>2020</b> , 40, 1282-1291	7.9	9
131	Wait Time for Curative Intent Radio Frequency Ablation is Associated with Increased Mortality in Patients with Early Stage Hepatocellular Carcinoma. <i>Annals of Hepatology</i> , <b>2017</b> , 16, 765-771	3.1	9

130	I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis. <i>F1000Research</i> , <b>2015</b> , 4, 95	3.6	9
129	Death from Liver Failure despite Lamivudine Prophylaxis during R-CHOP Chemotherapy due to Rapid Emergence M204 Mutations. <i>Case Reports in Hepatology</i> , <b>2013</b> , 2013, 454897	0.9	9
128	Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multi-center, multi-ethnic cohort (RETRACT-B study). <i>Gastroenterology</i> , <b>2021</b> ,	13.3	9
127	Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. <i>Cancer</i> , <b>2020</b> , 126, 1550-1558	6.4	9
126	Hepatitis C Virus Diagnostics: The Road to Simplification. <i>Clinical Liver Disease</i> , <b>2018</b> , 12, 125-129	2.2	9
125	Hepatitis B Reactivation: The Controversies Continue. <i>Digestive Diseases</i> , <b>2017</b> , 35, 351-358	3.2	8
124	Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 700-707	13.4	8
123	Resistance testing: Interpretation and incorporation into HCV treatment algorithms. <i>Clinical Liver Disease</i> , <b>2017</b> , 9, 115-120	2.2	8
122	Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 631-639	3.4	8
121	Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection. <i>Virology Journal</i> , <b>2016</b> , 13, 32	6.1	8
120	Optimal preservation of liver biopsy samples for downstream translational applications. <i>Hepatology International</i> , <b>2013</b> , 7, 758-66	8.8	8
119	Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection. <i>PLoS ONE</i> , <b>2013</b> , 8, e80003	3.7	8
118	Diagnosing Antibiotic Resistance Using Nucleic Acid Enzymes and Gold Nanoparticles. <i>ACS Nano</i> , <b>2021</b> , 15, 9379-9390	16.7	8
117	World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015. <i>Journal of Clinical Gastroenterology</i> , <b>2016</b> , 50, 691-703	3	8
116	Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 70, 2369-2376	11.6	8
115	Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. <i>Hepatology</i> , <b>2021</b> , 73, 2124-2140	11.2	8
114	Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 280-286	3.4	7
113	Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 69, 1969-1979	11.6	7

112	Replication and Oncolytic Activity of an Avian Orthoreovirus in Human Hepatocellular Carcinoma Cells. <i>Viruses</i> , <b>2017</b> , 9,	6.2	7
111	Psychiatric care during hepatitis C treatment: the changing role of psychiatrists in the era of direct-acting antivirals. <i>American Journal of Psychiatry</i> , <b>2015</b> , 172, 512-6	11.9	7
110	Hepatocellular carcinoma in a large Canadian urban centre: stage at treatment and its potential determinants. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2014</b> , 28, 150-4	2.8	7
109	Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020. <i>Hepatology Communications</i> , <b>2021</b> , 5, 911-922	6	7
108	Absolute Ligand Discrimination by Dimeric Signaling Receptors. <i>Biophysical Journal</i> , <b>2016</b> , 111, 917-20	2.9	7
107	Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study. <i>Hepatology Communications</i> , <b>2021</b> , 5, 478-490	6	7
106	Hepatitis B virus and hepatitis C virus treatment and management in patients receiving immune-modifying agents. <i>Current Opinion in Rheumatology</i> , <b>2014</b> , 26, 395-403	5.3	6
105	Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 31, 1018-27	6.1	6
104	Risk stratification in primary sclerosing cholangitis: comparison of biliary stricture severity on MRCP versus liver stiffness by MR elastography and vibration-controlled transient elastography. <i>European Radiology</i> , <b>2020</b> , 30, 3735-3747	8	5
103	Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response. <i>Scientific Reports</i> , <b>2016</b> , 6, 35410	4.9	5
102	HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection. <i>BMC Infectious Diseases</i> , <b>2016</b> , 16, 241	4	5
101	Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis. <i>Hepatology Communications</i> , <b>2019</b> , 3, 1388-1399	6	5
100	A Systematic Review and Meta-Analysis of Health Utilities in Patients With Chronic Hepatitis C. <i>Value in Health</i> , <b>2020</b> , 23, 127-137	3.3	5
99	Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 169-184	18.8	5
98	Global Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time Series Analysis. <i>Viruses</i> , <b>2021</b> , 13,	6.2	5
97	Genetic regulation of nonsense-mediated decay underlies association with risk of severe COVID-19 <b>2021</b> ,		5
96	The basis of liver regeneration: A systems biology approach. <i>Annals of Hepatology</i> , <b>2019</b> , 18, 422-428	3.1	4
95	Prevalence and predictors of complementary and alternative medicine modalities in patients with chronic hepatitis B. <i>Liver International</i> , <b>2019</b> , 39, 1418-1427	7.9	4

94	Risk of infections during interferon-based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 1057-64	4	4
93	Hepatitis C models of care: approaches to elimination. <i>Canadian Liver Journal</i> , <b>2020</b> , 3, 165-176	0.3	4
92	Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin. <i>Liver International</i> , <b>2018</b> , 38, 1571-1575	7.9	4
91	IL-15 and IFN- $\beta$ signal through the ERK pathway to inhibit HCV replication, independent of type I IFN signaling. <i>Cytokine</i> , <b>2019</b> , 124, 154439	4	4
90	High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 1896-1904	0.7	4
89	Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 1851-1859	4	4
88	The Ubiquitin-Specific Protease 18 Promotes Hepatitis C Virus Production by Increasing Viral Infectivity. <i>Mediators of Inflammation</i> , <b>2019</b> , 2019, 3124745	4.3	4
87	Precore and Basal Core Promoter Hepatitis B Virus (HBV) Variants Are Present From a Young Age and Differ Across HBV Genotypes. <i>Hepatology</i> , <b>2021</b> , 73, 1637-1651	11.2	4
86	Expert opinion on managing chronic HCV in patients with non-Hodgkin lymphoma and other extrahepatic malignancies. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 23-33	1.6	4
85	Direct-Acting Antivirals for Hepatitis C: Predictors of Early Discontinuation in the Real World. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2019</b> , 25, 697-704	1.9	3
84	Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 1127-1138	3.4	3
83	FRI-190-Incidence and predictors of flares after discontinuing nucleos (t) ide analogue therapy in HBeAg negative patients with chronic hepatitis B: Results from the randomized controlled STOP study. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e474	13.4	3
82	Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection. <i>Cells</i> , <b>2019</b> , 8,	7.9	3
81	Management of HCV in cirrhosis-a rapidly evolving landscape. <i>Current Gastroenterology Reports</i> , <b>2015</b> , 17, 443	5	3
80	GARNET: High SVR Rates Following Eight-Week Treatment with Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir for Patients with HCV Genotype 1b Infection. <i>American Journal of Gastroenterology</i> , <b>2016</b> , 111, S388	0.7	3
79	Prenatal hepatitis B screening, and hepatitis B burden among children, in Ontario: a descriptive study. <i>Cmaj</i> , <b>2020</b> , 192, E1299-E1305	3.5	3
78	Pitfalls in measuring temporal trends for late diagnosis of viral hepatitis. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 1251-1254	13.4	3
77	PS-139-Liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e89	13.4	3

76	Evolution of therapy for chronic hepatitis B: progressing from the simple to the complex. <i>Annals of Internal Medicine</i> , <b>2007</b> , 147, 806-8	8	3
75	Diagnostic accuracy of assays using point-of-care testing or dried blood spot samples for the determination of HCV RNA: a systematic review.. <i>Journal of Infectious Diseases</i> , <b>2022</b> ,	7	3
74	Update on the Risk of Primary and Recurrent HCC With the Use of DAA Therapy for HCV Infection. <i>Gastroenterology and Hepatology</i> , <b>2019</b> , 15, 303-306	0.7	3
73	Peginterferon-lambda for the treatment of COVID-19 in outpatients		3
72	Diagnosis of Chronic Hepatitis B Pericomplication: Risk factors and Trends Over Time. <i>Hepatology</i> , <b>2021</b> , 73, 2141-2154	11.2	3
71	A bivalent HCV peptide vaccine elicits pan-genotypic neutralizing antibodies in mice. <i>Vaccine</i> , <b>2020</b> , 38, 6864-6867	4.1	3
70	Reducing Read Time of Point-of-Care Test Does Not Affect Detection of Hepatitis C Virus and Reduces Need for Reflex RNA. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1451-1458.e4	6.9	3
69	Evaluation of Dried Blood Spot Testing for SARS-CoV-2 Serology Using a Quantitative Commercial Assay. <i>Viruses</i> , <b>2021</b> , 13,	6.2	3
68	Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 260-267	3.4	3
67	Peri-complication diagnosis of hepatitis C infection: Risk factors and trends over time. <i>Liver International</i> , <b>2021</b> , 41, 33-47	7.9	3
66	Inpatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 344-353	3.4	3
65	Hepatitis C: A Canadian perspective. <i>Canadian Liver Journal</i> , <b>2018</b> , 1, 1-3	0.3	3
64	Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 648420	8.4	3
63	Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 829-839	13.4	3
62	Hepatitis C virus infection. <i>Cmaj</i> , <b>2015</b> , 187, 1159	3.5	2
61	PS-178-Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e110	13.4	2
60	Hepatitis B reactivation in patients with solid tumors: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 138-138	2.2	2
59	Sofosbuvir + Ribavirin With or Without Peginterferon Is Well-Tolerated and Associated with High SVR Rates: Integrated Results from 4 Phase 3 Trials in HCV Genotype 1-6. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, S123	0.7	2

58	Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, 780-786	11.6	2
57	The impact of the first, second and third waves of covid-19 on hepatitis B and C testing in Ontario, Canada. <i>Journal of Viral Hepatitis</i> , <b>2021</b> ,	3.4	2
56	The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approach. <i>Liver International</i> , <b>2020</b> , 40, 51-59	7.9	2
55	Optimized ex vivo stimulation identifies multi-functional HBV-specific T cells in a majority of chronic hepatitis B patients. <i>Scientific Reports</i> , <b>2020</b> , 10, 11344	4.9	2
54	Impact of COVID-19 on Prescribing Trends of Direct-Acting Antivirals for the Treatment of Hepatitis C in Ontario, Canada. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 1738-1740	0.7	2
53	Clinical significance of quantitative e antigen in a cohort of hepatitis B virus-infected children and adults in North America. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 1042-1056	3.4	2
52	Cure prevents more than transmission of hepatitis C virus. <i>Hepatology</i> , <b>2016</b> , 64, 1003-4	11.2	2
51	Host-pathogen interactions in chronic HBV infection and transplantation of HCV-positive organs. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2019</b> , 16, 77-78	24.2	2
50	Validating viral hepatitis B and C diagnosis codes: a retrospective analysis using Ontario's health administrative data. <i>Canadian Journal of Public Health</i> , <b>2021</b> , 112, 502-512	3.2	2
49	The 7th Canadian Symposium on Hepatitis C Virus: □oward Elimination of HCV: How to Get There□ <i>Canadian Liver Journal</i> , <b>2018</b> , 1, 139-152	0.3	2
48	Host Genetic Variant in CXCL16 May Be Associated With Hepatitis B Virus-Related Acute Liver Failure. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , <b>2019</b> , 7, 477-479.e4	7.9	1
47	Letter to the Editor: Safety First: Favoring Prophylactic/Preemptive Over Delayed Treatment in D+/R- Transplants. <i>Hepatology</i> , <b>2020</b> , 72, 787	11.2	1
46	Commentary: what factors are important in diagnosing hepatic fibrosis?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 545-6	6.1	1
45	HBV treatment in a patient who will be receiving immunosuppressive therapy. <i>Clinical Liver Disease</i> , <b>2013</b> , 2, 34-37	2.2	1
44	Commentary: non-haemodynamic effects of beta-blockers in cirrhosis--more than meets the eye?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 652	6.1	1
43	Hepatitis B Biomarkers: Clinical Significance of the Old and the New. <i>Current Hepatitis Reports</i> , <b>2010</b> , 9, 187-196		1
42	Determinants of Ligand Specificity and Functional Plasticity in Type I Interferon Signaling. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 748423	8.4	1
41	Role of HVR1 sequence similarity in the cross-genotypic neutralization of HCV. <i>Virology Journal</i> , <b>2020</b> , 17, 140	6.1	1



40	Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, e799-e805	11.6	1
39	Protease inhibitors partially overcome the interferon nonresponse phenotype in patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , <b>2016</b> , 23, 340-7	3.4	1
38	Hepatitis C virus infection in mothers and children. <i>Canadian Liver Journal</i> , <b>2019</b> , 2, 210-224	0.3	1
37	HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 259-261	6.9	1
36	Maintained virological suppression and renal function with reduced dose tenofovir disoproxil fumarate in renally impaired chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 51-60	3.4	1
35	The 9th Canadian Symposium on Hepatitis C Virus: Advances in HCV research and treatment towards elimination. <i>Canadian Liver Journal</i> , <b>2021</b> , 4, 59-71	0.3	1
34	Health care costs associated with hepatitis C virus infection in First Nations populations in Ontario: a retrospective matched cohort study. <i>CMAJ Open</i> , <b>2021</b> , 9, E897-E906	2.5	1
33	Non-surgical management of advanced hepatocellular carcinoma: A systematic review by Cancer Care Ontario. <i>Canadian Liver Journal</i> , <b>2021</b> , 4, 257-274	0.3	1
32	Vascular Diseases of the Liver <b>2012</b> , 315-328		0
31	Chronic Viral Hepatitis in Adults and Children: Hepatitis B <b>2012</b> , 185-207		0
30	Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). <i>Canadian Liver Journal</i> , <b>2022</b> , 5, 61-90	0.3	0
29	The 8th Canadian Symposium on Hepatitis C virus: [Improving diagnosis and linkage to care] <i>Canadian Liver Journal</i> , <b>2020</b> , 3, 3-14	0.3	0
28	Spontaneous Clearance After Relapse Following Direct-Acting Antiviral Treatment for Chronic HCV Infection. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 2398-2406.e1	6.9	0
27	Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants. <i>BMC Public Health</i> , <b>2020</b> , 20, 1345	4.1	0
26	Viral hepatitis C cascade of care: A population-level comparison of immigrant and long-term residents. <i>Liver International</i> , <b>2021</b> , 41, 1775-1788	7.9	0
25	Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2016</b> , 2016, 6260271	2.8	0
24	Resolved HBV and anti-CD20 therapy. <i>Blood</i> , <b>2019</b> , 133, 104-106	2.2	0
23	Remaining challenges in HCV elimination. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 964-965	13.4	0

22	Hepatitis C virus infection in First Nations populations in Ontario from 2006 to 2014: a population-based retrospective cohort analysis. <i>CMAJ Open</i> , <b>2021</b> , 9, E886-E896	2.5	○
21	Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 1526-1538	3.4	○
20	Controlled Human Infection Model - Fast Track to HCV Vaccine?. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 1235-1240	59.2	○
19	Time Costs and Out-of-Pocket Costs in Patients With Chronic Hepatitis C in a Publicly Funded Health System.. <i>Value in Health</i> , <b>2022</b> , 25, 247-256	3.3	○
18	The Newest Direct-Acting Antiviral Agents: the Final Chapter in DAA Development. <i>Current Hepatology Reports</i> , <b>2018</b> , 17, 97-104	1	
17	Reply to: 'Evidence recommending antiviral therapy in hepatitis C'. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 1102-1103	3.4	
16	Response to Cytoplasmic rods and rings in ribavirin and Cytoplasmic rods and rings in mycophenolic acid treatment. <i>Liver International</i> , <b>2017</b> , 37, 1743-1744	7.9	
15	Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection. <i>International Journal of Drug Policy</i> , <b>2015</b> , 101669-101669	5.5	
14	Recomendaciones para el manejo de la infección por el virus de la hepatitis C entre usuarios de drogas por vía parenteral. <i>International Journal of Drug Policy</i> , <b>2015</b> , 101671	5.5	
13	HCV infection on-treatment viral kinetics: Do they still have a role?. <i>Clinical Liver Disease</i> , <b>2012</b> , 1, 51-53	2.2	
12	The lighter side of myeloma: an easily overlooked diagnosis. <i>Gut</i> , <b>2005</b> , 54, 1376, 1401	19.2	
11	Characterization of HCV-infected people who inject drugs (PWID) in the setting of clinical care in Canada (CAPICA): A retrospective study. <i>Canadian Liver Journal</i> , <b>2020</b> , 3, 358-371	0.3	
10	An update from the Canadian Association for the Study of the Liver on the management of liver disease during the COVID-19 pandemic. <i>Canadian Liver Journal</i> , <b>2020</b> , 3, 309-321	0.3	
9	Implications of Manganese in Chronic acquired hepatocerebral degeneration. <i>Annals of Hepatology</i> , <b>2018</b> , 17, 0-10	3.1	
8	Hepatitis C models of care: approaches to elimination. <i>Canadian Liver Journal</i> , <b>2020</b> , 3, 165-176	0.3	
7	An electronic prompt prior to myelosuppressive therapy to improve hepatitis B virus screening.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 6627-6627	2.2	
6	Hepatitis B virus screening before adjuvant chemotherapy in patients with early stage breast cancer: A cost-effectiveness analysis.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 6617-6617	2.2	
5	Natural History of the Cirrhotic Patient45-62		

4	Hepatitis B reactivation in patients with lymphoma: A meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 228-228	2.2
3	Reply to J. Cabezas et al. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 290-1	2.2
2	Hepatitis B Reactivation in the DAA Era: Minding the Gap Between the Black Box and Clinical Practice. <i>Current Hepatology Reports</i> , <b>2018</b> , 17, 444-450	1
1	Controversies in Treating Chronic Hepatitis B Virus Infection: Discordant Serologic Results. <i>Clinics in Liver Disease</i> , <b>2021</b> , 25, 805-816	4.6